What Wellthy Therapeutics does

Wellthy Therapeutics is a Mumbai-headquartered digital therapeutics company that builds and commercializes the wellthy CARE™ platform, a globally regulated, cloud-based Software-as-a-Medical-Device (SaMD) operating system for chronic disease management. The platform combines AI/ML-powered personalization with Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) led digital interventions, remote patient monitoring via connected medical devices (glucometers, BP monitors), and human health-coach touchpoints in a 'phygital' care model, covering 8 therapeutic areas including Type 2 Diabetes, Hypertension, Dyslipidemia, Congestive Heart Failure, Ischemic Heart Disease, Clinical Obesity, Chronic Kidney Disease, and Asthma.

The platform is supported by an unusually comprehensive regulatory and quality stack — CE Mark (Class 1 under EU MDR 2017/745), ISO 13485:2016, ISO 14971:2019, ISO 27001:2013, ISO 27701:2019, IEC 62304:2006, GDPR, CDSCO registration, FDA CFR Part 11 and Part 820, and HIPAA — enabling Wellthy to act as manufacturer-of-record for global life science partners and to deliver culturally localized content across Indian regional languages (Hindi, Kannada) and international markets. The company's clinical credibility is anchored in 20–30+ peer-reviewed publications across JMIR, ADA, ACC, IDF, ATTD, and ADCES, and demonstrated outcomes including 1.1% absolute HbA1C reduction, 90% medication adherence uplift, 85% pain reduction in rheumatoid arthritis, 61% cholesterol reduction, and a 98% successful pregnancy delivery rate.

Wellthy serves pharmaceutical, insurance, and medical device enterprises — including Roche Diabetes Care, Cipla, Pfizer, Abbott, ResMed, Bayer G4A, Ferrer, Intas, Manipal Cigna, Aviva, Swiss Re, RGA, and DHFL Pramerica — through platform licensing, co-development of companion SaMD products, standalone DTx products, and digital health advisory services. It also operates a direct-to-consumer wellthy CARE app with 100,000+ downloads (4.6/5 rating) used primarily as a patient engagement and real-world evidence layer. The company expanded into the US (May 2023) and Japan (June 2023), and was acquired by TruDoc in February 2024 to accelerate digital health delivery across the GCC region and India.

Name

Wellthy Therapeutics

Legal name

Wellthy Therapeutics Private Limited

Website

https://wellthytherapeutics.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

101–250 employees

Short description

Wellthy Therapeutics builds the globally regulated, AI-powered wellthy CARE™ digital therapeutics platform, delivering companion SaMD and standalone CBT/ACT-based programs across 8 therapeutic areas to pharmaceutical, insurance, and medical device partners including Roche, Pfizer, Abbott, Cipla, and Manipal Cigna.

Ownership category

akta.pro rank

Product category

Digital Therapeutics Software

NAICS

Custom Computer Programming Services (541511), Ambulatory Health Care Services (621)

SIC

Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000)

akta.pro primary industry

DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)

akta.pro secondary industries

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

Keywords

• Digital therapeutics platform
• Chronic disease management
• Software as medical device
• Behavioral health interventions
• Patient support programs

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Licensing to Life Science Partners: Wellthy licenses its wellthy CARE platform to pharmaceutical companies, medical device manufacturers, insurers, and healthcare systems. Partners use the platform to build and deploy digital therapeutic solutions for their patients and customers. Revenue is generated through licensing fees, platform access fees, and co-development costs. This is the primary revenue stream.
2. Digital Health Advisory and Consulting Services: Wellthy provides end-to-end consulting services to life science companies looking to build SaMD solutions in-house. Services span discovery, design, clinical development, regulatory navigation, and commercialization support. Revenue is generated through project-based consulting engagements.
3. Companion SaMD and Standalone DTx Products: Wellthy develops and commercializes both companion Software as a Medical Device (SaMD) products used in combination with drugs or devices, and standalone digital therapeutics prescribed for unmet patient needs. Revenue from these products may flow through pharmaceutical co-promotion, payer reimbursement, or direct B2B2C models.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels10 records

Core offering

Wellthy Therapeutics licenses its wellthy CARE platform — a globally regulated, AI/ML-powered digital therapeutics operating system — to pharmaceutical, insurance, medical device, and healthcare system partners. Partners use the modular DTx/SaMD platform to build, deploy, and commercialize companion Software as a Medical Device solutions, standalone digital therapeutics, patient support programs, and remote patient monitoring products for chronic disease management across 8 therapeutic areas. The company also provides digital health advisory services covering SaMD discovery, clinical development, regulatory navigation, and commercialization support.

Product overview

Wellthy Therapeutics offers a platform-plus-modules architecture centered on the wellthy CARE™ platform, a globally regulated DTx operating system. The core platform enables biopharma, med device, insurance, and healthcare system partners to build and deploy Software as a Medical Device (SaMD) solutions. Key product modules include Companion SaMD, Standalone DTx (CBT/ACT-based), Patient Support Programs, and Remote Patient Monitoring capabilities. Additional services include Digital Health Advisory consulting for regulatory and development support.

Differentiator

Problem solved

Functional benefit

Brands

• Wellthy CARE: Digital care platform and operating system for digital therapeutic solutions

Products and services

• wellthy CARE Platform A globally regulated, modular, cloud-based DTx/SaMD operating system that serves as the foundation for building companion Software as a Medical Device solutions, standalone digital therapeutics, patient support programs, and remote patient monitoring for pharmaceutical, insurance, medical device, and healthcare system partners. Features AI/ML-powered personalization, CBT/ACT-led behavioral interventions, and multilingual therapy delivery across multiple therapeutic areas including Type 2 Diabetes, Hypertension, Dyslipidemia, Congestive Heart Failure, Ischemic Heart Disease, Clinical Obesity, Chronic Kidney Disease, and Asthma.
• Companion SaMD Clinically validated Software as a Medical Device solutions built to be used in combination with drug therapy or medical devices to improve the real-world effectiveness, adherence, and outcomes of those existing treatments. Targeted at pharmaceutical and medical device companies seeking to augment their products with companion digital therapeutics.
• Standalone DTx Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) led digital therapeutics that can be prescribed standalone to address unmet patient needs for specific chronic conditions. Marketed to pharmaceutical, insurance, and healthcare system partners for prescription to patient populations with complex clinical needs.
• Patient Support Programs Digital therapy-led patient support programs for pharmaceutical and life science partners that track and monitor digital biomarkers, improve patient engagement, medication adherence, and outcomes across chronic disease management. Designed to be deployed as embedded programs within pharma Patient Support Programs and insurance customer engagement initiatives.
• Remote Patient Monitoring Solutions to remotely monitor patient progress through continual patient-reported and connected device-driven data streams (integrating with glucometers, BP monitors, and other medical devices), enabling personalized just-in-time interventions and clinical decision support for healthcare providers and life science partners.
• Digital Health Advisory Services End-to-end consulting services for life science companies looking to build SaMD solutions in-house, spanning discovery, design, clinical development, regulatory navigation, evidence generation, and commercialization support. Delivered through project-based engagements with pharmaceutical, medical device, and insurance partners.

Quantifiable outcome

• 85% reduction in pain for RA (rheumatoid arthritis) patients
• +12 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature6 records

Partnerships

15 partnerships are on record, tiered flagship and core.

• TruDocflagshipStrategic or Co-development Partner · 13 February 2024TruDoc acquired Wellthy Therapeutics in February 2024 to deliver premier digital health services in the GCC (Gulf Cooperation Council) region and expand into India. The acquisition combines TruDoc's existing digital health capabilities with Wellthy's DTx platform, evidence base, and Asian market expertise to create a comprehensive digital health provider across MENA and India.
• Ferrer (Spain)coreStrategic or Co-development Partner · 27 February 2020Spanish pharmaceutical leader Ferrer partnered with Wellthy Therapeutics for digital therapeutic solutions. The partnership focused on co-creating patient support programs leveraging Wellthy's clinically validated DTx platform to improve patient outcomes across Ferrer's therapeutic areas.
• Bayer G4AcoreStrategic or Co-development Partner · 7 March 2019Bayer G4A selected Wellthy Therapeutics as a partner for digital health innovation, recognizing Wellthy's platform capabilities in chronic disease management and DTx solution development for unmet patient needs.
• CiplacoreStrategic or Co-development Partner · 21 February 2019Cipla partnered with Wellthy Therapeutics to offer digital therapeutics for diabetes and cardiovascular diseases, augmenting Cipla's product portfolio with digital health software for improved medication management and patient monitoring.
• Roche Diabetes Care IndiacoreStrategic or Co-development Partner · 28 November 2018Roche Diabetes Care India partnered with Wellthy Therapeutics to offer an AI-based digital diabetes coaching solution for Accu-Chek Active glucometer users. The partnership combined Roche's device ecosystem with Wellthy's DTx platform to address clinical inertia and improve patient outcomes. Results demonstrated 130% increase in blood glucose monitoring frequency and reduced glucose variability among enrolled patients.
• Wockhardt Hospital SOBOcoreStrategic or Co-development Partner · 21 November 2018Wockhardt Hospital in South Mumbai launched a diabetes clinic powered by Wellthy Therapeutics in November 2018, integrating digital therapeutic solutions into the hospital's chronic disease management program for diabetes patients.
• Swiss RecoreStrategic or Co-development Partner · 10 August 2017Global reinsurance leader Swiss Re engaged with Wellthy Therapeutics through its 2017 InsurTech Accelerator program, exploring digital health integration for insurance risk management and product innovation.
• PfizercoreStrategic or Co-development PartnerPfizer is listed as a partner on Wellthy's platform page. The nature of the partnership involves combining Pfizer's pharmaceutical products with Wellthy's digital therapeutic platform to improve patient outcomes and engagement.
• AbbottcoreStrategic or Co-development PartnerAbbott is listed as a partner on Wellthy's platform page. The partnership leverages Wellthy's DTx platform with Abbott's healthcare products to deliver integrated patient care solutions.
• ResMedcoreStrategic or Co-development PartnerResMed partnered with Wellthy Therapeutics as part of the medical devices partnership ecosystem. The collaboration focuses on DTx-based solutions to enhance medical device adherence and boost patient lifetime value through improved therapy outcomes.
• Intas PharmaceuticalscoreStrategic or Co-development PartnerIntas Pharmaceuticals is listed as a partner on Wellthy's platform page, indicating collaboration on digital therapeutic solutions for chronic disease management.
• Manipal CignacoreStrategic or Co-development PartnerManipal Cigna partnered with Wellthy Therapeutics for health insurance digital care integration. The partnership delivers evidence-based remote care for chronic insured patients, demonstrating significant BP and blood sugar reduction outcomes. Wellthy's platform enabled the insurer to engage chronic disease patients and balance risk through improved health outcomes.
• AvivacoreStrategic or Co-development PartnerAviva partnered with Wellthy Therapeutics to integrate digital therapeutics into insurance products, aiming to develop healthier insured patient cohorts and offer innovative insurance products with value-based care components.
• RGAcoreStrategic or Co-development PartnerRGA (Reinsurance Group of America), a leading reinsurance company, partnered with Wellthy Therapeutics as part of its digital health ecosystem, exploring integration of DTx solutions into reinsurance products for improved risk assessment and patient outcomes.
• DHFL Pramerica Life InsurancecoreStrategic or Co-development PartnerDHFL Pramerica Life Insurance Company partnered with Wellthy Therapeutics to enable evidence-based remote care for chronic insured patients. Wellthy's digital therapeutic platform was used to provide protocol-driven virtual care pathways during the COVID-19 pandemic, helping reduce exposure risk while maintaining care continuity for chronic disease patients.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Omada Health: US digital health company delivering virtual care programs for chronic conditions (diabetes, hypertension, obesity) with a B2B distribution model targeting employers, insurers, and health systems. Closely comparable to Wellthy in B2B chronic-disease digital therapeutic delivery and outcomes-based contracting.
• DarioHealth: Digital chronic condition management platform integrating connected devices (glucometers, BP monitors) with AI-driven coaching, sold to employers, health plans, and pharma. Comparable to Wellthy on device-integration, multi-therapeutic-area coverage, and B2B2C distribution.
• Voluntis (now part of AptarGroup): Digital therapeutics company historically focused on SaMD for oncology, diabetes, and hemophilia, with deep pharmaceutical and medical-device partnerships. Comparable to Wellthy on the SaMD platform play and enterprise biopharma business model.
• Better Therapeutics: Prescription digital therapeutics company developing FDA-regulated software for cardiometabolic conditions including type 2 diabetes and hypertension. Highly comparable to Wellthy on the condition-specific DTx positioning and regulatory clearance pathway.
• Noom Health: Digital health platform combining AI-driven behavioral coaching with CBT-inspired interventions for chronic disease and weight management. Comparable to Wellthy on the behavioral-science-led intervention design and enterprise/insurer distribution model.
• Livongo (Teladoc Health): Digital chronic disease management platform (now part of Teladoc Health) combining connected devices, AI coaching, and behavioral science. Comparable to Wellthy on the device-integration plus CBT-style coaching model across diabetes, hypertension, and cardiometabolic conditions.
• Propeller Health (ResMed): Digital therapeutic platform for respiratory conditions combining connected inhaler sensors, patient engagement, and clinical decision support, now part of ResMed. Comparable to Wellthy on the connected-device-plus-DTx model and medical-device partnership channel (Wellthy already partners with ResMed).
• Akili Interactive: Digital therapeutics company with FDA-cleared cognitive therapy products and a B2B2C distribution model via pharma, payers, and providers. Comparable to Wellthy on the regulated software-as-medicine positioning and enterprise sales motion.
• Pear Therapeutics: Pioneer in prescription digital therapeutics with FDA-cleared PDT products in substance use disorder, insomnia, and ADHD. Comparable to Wellthy on regulated DTx platform positioning and behavioral-science-led therapy design.

Broad incumbents

• Hinge Health: Large-scale digital MSK and chronic pain care platform combining wearable sensors, AI, and human coaching distributed through employers and health plans. Comparable to Wellthy in the broader phygital digital care model and enterprise payer distribution, but at materially larger scale and on a different therapeutic area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/wellthy-therapeutics-504058713088365
• LinkedInlinkedin.com/company/wellthytherapeutics
• Instagraminstagram.com/wellthytherapeutics
• Xx.com/wellthy_care

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellthy Therapeutics